Correvio Pharma Corp. CORV

why it is very risky to invest?

[mingzhu]

1, $44 m USD  debt
2, cash run out by the middle of 2020
3, debt to capital ratio 2:1
such stock is only good for a trade not invetment.

[bigkagan]

they still have Trevyent approval pending in April and Brinavess could be allowed under the Right-To-Try Act in the US

[mingzhu]

it does not mean much even FED approves Treyent because CORV has no right to sell in U.S. Only United tech has U.S right. CORV can only use the document to apply for approval in EU. It will take long long time. no much revenue if you can do  right to try. besides It lost over $10m last Q.  i will buy for dead cat bounce after down 20%. more, perhaps in 0.20s.

[bigkagan]

it's still too early to bury CORV because they'll make $30 mil, in revenue this year. Their problem has been too many expenses but now they're saying they''ll cut them in N.America so maybe they could finally squeeze out some profit To conserve its financial resources, Correvio intends to reduce its operating costs in North America, while concentrating its resources on only

[bigkagan]

bought some more today to average down for the fraction of the price I paid when it was above $3, remember that it was in the $4's a year ago without any US Brinavess, let's go, hee 

[bigkagan]

Consequently, on December 10, 2019, the FDA voted against approval of the NDA. On this news, Correvio shares fell 67% to close at $0.46 per share. The stock continues to decline. Read more at https://stockhouse.com/news/press-releases/2019/12/16/shareholder-alert-robbins-llp-announces-correvio-pharma-corp-corv-sued-for#uwbH00Q4hDgAIVIw.99 These lawyers are lying, the FDA hasn't yet officially

[bigkagan]

may be there be good news tomorrow and Happy Holidays to everybody 

[rosaria22]

This post has been removed in accordance with Community Policy

[slithey]

This is nearly following William Hunter's playbook with angiotech some years ago: develop a drug product with decent sales, expand through acquisitions taking on debt at high interest that were out of line with reasonable profit projections, and then having the lenders acquire it to settle the debt. Compared to ANP at least you guys get your 42 cents. ANP paid the shareholders nothing. In both